From Yahoo Board, Investor Relations update:
Update...
Just got off the phone with Brian Luque. I asked 3 questions, which I had referred to in an email last week.
Q: Investors have been concerned about the wording "indefinite" in the 8K that announced uplisting would be delayed. Does that mean that the uplisting has been "canceled" or is InVivo taking steps to perform the necessary changes in corporate governance cited in their news release about uplisting?
A: InVivo did not mean that the uplisting was canceled, just that they had to take steps before uplisting and they didn't know the exact time this would require. Brian said he was actually quite upset that the lawyers had made them use the wording, "indefinite". But he emphasized that they have already taken steps and are still engaged in the process of preparing to uplist. However, he noted they cannot issue a PR just yet about uplisting schedule.
Q: InVivo has stated that the biopolymer scaffold patient implants are estimated to begin early fall, with meetings involving hospital Institutional Review Boards (IRBs) necessary before they can begin trials. Does InVivo believe patient implants will be on-track for early fall?
A: InVivo anticipates the IRB approvals will enable patient implants to begin in early fall for the biopolymer scaffold.
Q: InVivo has stated that their application to FDA for methyl prednisolone hydrogel would be on a separate track expected for submission in early fall. Is this schedule still anticipated to be met?
A: Yes, InVivo anticipates FDA submission to occur within their projected timeframe.
AI
